ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
ICON CIO – Telemedicine, Wearables & AI Could Boost Clinical Trial Participation
A Diginomica article featuring commentary from Tom O’Leary, discussing the opportunities for technology to overcome key challenges in clinical trials.
Embracing Digital Health
An article by Vicki Anastasi, Matt McCarty & Marie McCarthy, on the skills & expertise needed to best use mHealth to transform clinical trials.
Converging Goals: How a Focus on the Patient Drives Stronger Healthcare Partnerships
The foundation of healthcare is shifting from a provider- based to a patient-centric, or value-based, model. Read more in this recent MPO Magazine article.
How ICON is Using Analytics & Wearables to Enhance Clinical Trials
The company is investing in emergent technology to boost the attractiveness of trials as a care option and attract more participants.
21st Century Cures Act: Ushering in a New Chapter in the Expanding Use of Real-World Evidence
A recent ICON article published by PharmaFocus on the 21st Century Cures Act and the relative expanding use of real-world evidence (RWE).
Patients is a Virtue
An article on patient service solutions, featuring commentary from Matt McCarty, Kelly Franchetti and Gretchen Goller
Next Generation of Clinical Trials
In this edition of PharmaTimes, ICON's Tom O’Leary comments on the next generation of trials in particular participant engagement, expansive data & digital tech
Wearables in Virtual Trials
Connected health including wearable devices and mobile health (mHealth) technology, is providing an opportunity for patient-centric data.
Navigating the Labyrinth of Regulation and Taking Drug Safety Reporting to the Next Level with Automation
An article on the challenges of global clinical trials in an ever- changing regulatory environment, and more.
Special Report on Immunology & Autoimmunity: Turn of the coin
A Drug Discovery News (DDN) article featuring commentary from ICON expert Marco Silleni, discussing the challenges of autoimmune disorders.